Target Name: CDC27
NCBI ID: G996
Review Report on CDC27 Target / Biomarker Content of Review Report on CDC27 Target / Biomarker
CDC27
Other Name(s): CDC27 variant 4 | cell division cycle 27 | D0S1430E | Cell division cycle protein 27 homolog | Cell division cycle protein 27 homolog (isoform 3) | CDC27 variant 2 | Anaphase promoting complex subunit 3 | Cell division cycle 27, transcript variant 4 | Cell division cycle 27, transcript variant 1 | HNUC | anaphase promoting complex subunit 3 | H-NUC | CDC27 variant 1 | cell division cycle 27 homolog | Cell division cycle protein 27 homolog (isoform 2) | Cell division cycle 27 homolog | D17S978E | D0S1430E, D17S978E | CDC27 homolog | Cell division cycle protein 27 homolog (isoform 1) | nuc2 homolog | Cell division cycle 27, transcript variant 2 | Nuc2 homolog | Anaphase-promoting complex subunit 3 | CDC27_HUMAN | Cell division cycle protein 27 homolog (isoform 4) | APC3 | Cell division cycle 27, transcript variant 3 | ANAPC3 | Anaphase-promoting complex, protein 3 | anaphase-promoting complex, protein 3 | CDC27 variant 3 | NUC2 | CDC27Hs

A closer look at CDC27: A potential drug target and biomarker

CDC27 is a protein that is expressed in various tissues of the body, including the lungs, heart, kidneys, and intestines. It is a key regulator of cell growth and differentiation, and is involved in the development and maintenance of tissues. In recent years, researchers have identified potential drug targets and biomarkers for CDC27, which has led to a growing interest in this protein and its potential role in disease. In this article, we will provide a comprehensive overview of CDC27, including its structure, function, and potential drug targets.

Structure and function

CDC27 is a 21-kDa protein that is composed of 215 amino acid residues. It has a unique fold structure that is characterized by a long N-terminus, a single transmembrane region, and a C-terminus that is involved in its cell surface localization. CDC27 is involved in the regulation of cell growth, differentiation, and survival, and is a key regulator of the G1/S transition, which is a critical step in the cell cycle.

CDC27 is also involved in the regulation of cell-cell adhesion, and is thought to play a role in the development and maintenance of tissues such as the placenta and the gut epithelium. It is also involved in the regulation of angiogenesis, which is the process by which new blood vessels are formed.

CDC27 has been identified as a potential drug target due to its involvement in the regulation of cell growth and differentiation, as well as its role in the development and maintenance of tissues. Several studies have shown that modulating CDC27 activity can have a significant impact on the behavior of cancer cells, including the inhibition of cell proliferation and the inhibition of angiogenesis.

Potential drug targets

Several potential drug targets have been identified for CDC27, including the inhibition of its activity in cell growth and the inhibition of its role in the development and maintenance of tissues. The inhibition of CDC27 activity has been shown to have a positive impact on the growth and survival of cancer cells, and has been used as a therapeutic approach in several studies.

One potential drug target for CDC27 is the inhibition of its activity in cell growth. Several studies have shown that the inhibition of CDC27 activity can have a significant impact on the growth and survival of cancer cells, including the inhibition of the inhibition of cell proliferation.

Another potential drug target for CDC27 is the inhibition of its role in the development and maintenance of tissues. Several studies have shown that the inhibition of CDC27 activity can have a significant impact on the behavior of tissues, including the inhibition of tissue formation and the inhibition of angiogenesis.

Biomarkers

The identification of biomarkers for CDC27 has also been an exciting area of research. Several studies have shown that the expression of CDC27 is involved in the regulation of important biological processes, including cell growth, differentiation, and survival. The identification of biomarkers for CDC27 may have a significant impact on the development of new diagnostic tests and the development of new therapeutic approaches.

Conclusion

In conclusion, CDC27 is a protein that is involved in the regulation of cell growth and differentiation, and has been identified as a potential drug target due to its involvement in the development and maintenance of tissues. The inhibition of CDC27 activity has been shown to have a positive impact on the growth and survival of cancer cells, and several potential drug targets have been identified for this protein. Further research is needed to fully understand the role of CDC27 in disease and to develop new diagnostic tests and therapeutic approaches.

Protein Name: Cell Division Cycle 27

Functions: Component of the anaphase promoting complex/cyclosome (APC/C), a cell cycle-regulated E3 ubiquitin ligase that controls progression through mitosis and the G1 phase of the cell cycle. The APC/C complex acts by mediating ubiquitination and subsequent degradation of target proteins: it mainly mediates the formation of 'Lys-11'-linked polyubiquitin chains and, to a lower extent, the formation of 'Lys-48'- and 'Lys-63'-linked polyubiquitin chains

The "CDC27 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CDC27 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

CDC27P2 | CDC34 | CDC37 | CDC37L1 | CDC37P1 | CDC40 | CDC42 | CDC42BPA | CDC42BPB | CDC42BPG | CDC42EP1 | CDC42EP2 | CDC42EP3 | CDC42EP4 | CDC42EP5 | CDC42SE1 | CDC42SE2 | CDC45 | CDC5L | CDC5L complex | CDC6 | CDC7 | CDC73 | CDCA2 | CDCA3 | CDCA4 | CDCA4P3 | CDCA5 | CDCA7 | CDCA7L | CDCA8 | CDCP1 | CDCP2 | CDH1 | CDH10 | CDH11 | CDH12 | CDH13 | CDH13-AS2 | CDH15 | CDH16 | CDH17 | CDH18 | CDH19 | CDH2 | CDH20 | CDH22 | CDH23 | CDH24 | CDH26 | CDH3 | CDH4 | CDH5 | CDH6 | CDH7 | CDH8 | CDH9 | CDHR1 | CDHR18P | CDHR2 | CDHR3 | CDHR4 | CDHR5 | CDIN1 | CDIP1 | CDIPT | CDIPTOSP | CDK1 | CDK10 | CDK11A | CDK11B | CDK12 | CDK13 | CDK14 | CDK15 | CDK16 | CDK17 | CDK18 | CDK19 | CDK2 | CDK20 | CDK2AP1 | CDK2AP2 | CDK2AP2P2 | CDK2AP2P3 | CDK3 | CDK4 | CDK5 | CDK5R1 | CDK5R2 | CDK5RAP1 | CDK5RAP2 | CDK5RAP3 | CDK6 | CDK6-AS1 | CDK7 | CDK8 | CDK9 | CDKAL1 | CDKL1